Specification of Drug Substances and Products: Development and Validation of Analytical Methods

Riley PhD, Christopher M.; Rosanske, Thomas W.

ISBN 10: 0080983502 / ISBN 13: 9780080983509

Published by Elsevier (edition 1), 2013

About this Item

The item is brand new, never used or read. It's in perfect condition and may include supplements and/or access codes or come shrink-wrapped.

Seller Inventory # 0080983502-10-1

Bibliographic Details

• Title: Specification of Drug Substances and Products: Development and Validation of Analytical Methods
• Publisher: Elsevier (edition 1)
• Publication Date: 2013
• Language: English
• ISBN 10: 0080983502
• ISBN 13: 9780080983509
• Binding: Hardcover
• Edition: 1.
• Condition: New

About this title

Synopsis

Specification of Drug Substances and Products: Development and Validation of Analytical Methods is a comprehensive and critical analysis of the requirements and approaches to setting specifications for new pharmaceutical products, with an emphasis on phase-appropriate development and validation of analytical methods. This book is intended as more than a review of new regional guidelines, existing regulatory guidance, and industry practices. It provides a hands-on guide to understanding and applying these in practice. The authors discuss critical issues, novel approaches, and future directions while also providing insight into how International Guidelines were developed and the rationale behind them.

• Guide to industry best practices of analytical methodologies used in the specification of new drug substances and products (e.g. DOE, QbD)
• Critical assessment of the application of ICH guidelines on method validation and specification setting, written by experts involved in the development and application of the guidelines to aid understanding of requirements and what is expected by regulatory authorities
• Direct applicability to the day-to-day activities in drug development and the potential to increase productivity

About the Authors

Dr. Christopher Riley is the President of Riley and Rabel Consulting Services. He received a bachelor’s degree in Pharmacy (1977) and PhD degree in Pharmaceutical Chemistry (1980) from the University of Bath, UK. He taught Pharmaceutical Chemistry, at the Universities of Florida (1983-6) and the University of Kansas (1986-94), and was a Vice President at DuPont Merck (1994-2001) and ALZA (a division of J&J) (2001-7). He has coauthored more than 140 book chapters and papers in peer-reviewed journals, as well as 5 books. He has extensive experience in CMC regulatory affairs and the development of all types of dosage forms.

Former Director of Business Development at Acceleration Laboratory Services, Incorporated. He has previously held scientific and senior management positions at The Upjohn Company, Marion Laboratories, Marion Merrell Dow, Hoechst Marion Roussel, Quintiles, Eli Lilly, Beckloff Associates, and PPD. He currently serves on a Small Molecule USP Expert Committee.